Development of a novel biocompatible polymer system for extended drug release in a next-generation drug-eluting stent

被引:53
作者
Udipi, Kishore [1 ]
Chen, Mingfei [1 ]
Cheng, Peiwen [1 ]
Jiang, Kevin [1 ]
Judd, Diane [1 ]
Caceres, Alejandra [1 ]
Melder, Robert J. [1 ]
Wilcox, Josiah N. [1 ]
机构
[1] Medtron CardioVasc, Santa Rosa, CA 95403 USA
关键词
biocompatibility; drug-eluting stents; controlled drug release; hydrophilicity; durability;
D O I
10.1002/jbm.a.31664
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Drug-eluting stents have proven superior to bare metal stents with lower restenosis rates. Local delivery of drugs from these stents is achieved in most cases with the help of biostable polymer coatings. However, since the polymer coating remains in the body well after all the drug is released, patients can potentially develop hypersensitivity to these polymers-leading to complications such as late-stent thrombosis. It is therefore important that the polymers are designed to be biocompatible and well tolerated by the body. The polymer coatings are also expected to be robust and provide good control over elution of the desired drug. This paper describes the development of a unique, proprietary polymer blend system, specially designed to meet these requirements. Mutually compatible, free-radical-initiated elastomeric polymers were designed to provide a robust coating and offer a steady, sustained release of the highly hydrophobic drug zotarolimus over an extended period. The polymer blend system is also well tolerated by the hydrophilic environment in vivo, as demonstrated through porcine studies. (C) 2007 Wiley Periodicals, Inc.
引用
收藏
页码:1064 / 1071
页数:8
相关论文
共 27 条
[1]   A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents [J].
Babapulle, MN ;
Joseph, L ;
Bélisle, P ;
Brophy, JM ;
Eisenberg, MJ .
LANCET, 2004, 364 (9434) :583-591
[2]   Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy [J].
Bennett, MR ;
O'Sullivan, M .
PHARMACOLOGY & THERAPEUTICS, 2001, 91 (02) :149-166
[3]  
Buellesfeld L, 2004, HERZ, V29, P167, DOI 10.1007/s00059-004-2557-5
[4]   Experimental efficacy of an everolimus eluting cobalt chromium stent [J].
Carter, AJ ;
Brodeur, A ;
Collingwood, R ;
Ross, S ;
Gibson, L ;
Wang, CA ;
Haller, S ;
Coleman, L ;
Virmani, R .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2006, 68 (01) :97-103
[5]  
CARTER AJ, UNPUB PHARMACOKINETI
[6]   Comparison of short- and mid-term outcomes between CYPHER and TAXUS stents in patients with complex lesions of the coronary arteries [J].
Chen, JL ;
Gao, RL ;
Yang, YJ ;
Qiao, SB ;
Qin, XW ;
Yao, M ;
Liu, HB ;
Xu, B ;
Wu, YJ ;
Yuan, JQ ;
Chen, J ;
Dai, J ;
You, SJ ;
Ma, WH .
CHINESE MEDICAL JOURNAL, 2006, 119 (01) :21-25
[7]  
EDELMAN ER, 1998, IN PRESS AM J CARDIO, V81
[8]  
FAJADET J, IN PRESS CIRCULATION
[9]   Morphological predictors of restenosis after coronary stenting in humans [J].
Farb, A ;
Weber, DK ;
Kolodgie, FD ;
Burke, AP ;
Virmani, R .
CIRCULATION, 2002, 105 (25) :2974-2980
[10]   Drug-eluting stents in vascular intervention [J].
Fattori, R ;
Piva, T .
LANCET, 2003, 361 (9353) :247-249